Treating thrombotic thrombocytopenic purpura without plasma exchange during the COVID-19 pandemic. A case report and a brief literature review.
Transfus Apher Sci
; 60(3): 103107, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1104307
ABSTRACT
We report the case of a patient diagnosed with a clinical relapse of acquired immune-mediated thrombotic thrombocytopenic purpura (TTP) who was successfully treated with low-dose rituximab plus corticosteroids without the use of plasma exchange (PEx), which was unavailable at the time due to the COVID-19 pandemic. Rituximab 100 mg weekly for 4 weeks was administered, combined with 1 mg/kg of prednisone, obtaining a complete hematological response in 6 weeks. This case suggests that PEx may be unnecessary for a subset of patients with relapsed TTP who are clinically stable without significant end-organ damage. A brief literature review regarding TTP patients treated without plasma exchange is also included.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Intercambio Plasmático
/
Púrpura Trombocitopénica Trombótica
/
COVID-19
Tipo de estudio:
Reporte de caso
/
Estudio observacional
/
Estudio pronóstico
/
Revisiones
Límite:
Adulto
/
Femenino
/
Humanos
/
Young_adult
Idioma:
Inglés
Revista:
Transfus Apher Sci
Asunto de la revista:
Hematología
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
J.transci.2021.103107
Similares
MEDLINE
...
LILACS
LIS